Skip to Content

News & Events

Press Releases

Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryDec 5, 2005	Vertex Pharmaceuticals Announces Start of Phase II Clinical Development for Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 - Investigational New Drug Application Activated in the U.S. - General Business	View HTML Vertex Pharmaceuticals Announces Start of Phase II Clinical Development for Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 12.9 KB
Toggle SummaryDec 5, 2005	Vertex Pharmaceuticals Announces Start of Phase II Clinical Development for Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 - Investigational New Drug Application Activated in the U.S. - HCV	View HTML Vertex Pharmaceuticals Announces Start of Phase II Clinical Development for Investigational Oral Hepatitis C Virus Protease Inhibitor VX-950 12.9 KB
Toggle SummaryNov 18, 2005	FDA Approves Updated Labeling for LEXIVA - Coadministration With Esomeprazole Does Not Affect Blood Levels of LEXIVA - General Business	View HTML FDA Approves Updated Labeling for LEXIVA 15.1 KB
Toggle SummaryNov 18, 2005	FDA Approves Updated Labeling for LEXIVA - Coadministration With Esomeprazole Does Not Affect Blood Levels of LEXIVA - General Business	View HTML FDA Approves Updated Labeling for LEXIVA 15.1 KB
Toggle SummaryNov 11, 2005	AASLD Presentations Support the Initiation of a Broad Phase II Program with VX-950, an Investigational Oral HCV Protease Inhibitor Vertex Announces Filing of IND in Support of VX-950 Phase II Development in the U.S. HCV	View HTML AASLD Presentations Support the Initiation of a Broad Phase II Program with VX-950, an Investigational Oral HCV Protease Inhibitor 23.9 KB
Toggle SummaryNov 9, 2005	Vertex Pharmaceuticals Announces a Conference Call and Webcast to Review VX-950 Presentations at the Upcoming AASLD Meeting Vertex Pharmaceuticals Announces a Conference Call and Webcast to Review VX-950 Presentations at the Upcoming AASLD Meeting Cambridge, MA, November 9, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will host a conference call and webcast on Friday, November 11, 2005 at 9:00 a.m. EST. Webcasts	View HTML Vertex Pharmaceuticals Announces a Conference Call and Webcast to Review VX-950 Presentations at the Upcoming AASLD Meeting 7.8 KB
Toggle SummaryOct 31, 2005	Vertex Pharmaceuticals Announces Resignation of N. Anthony Coles, M.D., as Senior Vice President, Commercial Operations Vertex Pharmaceuticals Announces Resignation of N. Anthony Coles, M.D., as Senior Vice President, Commercial Operations Cambridge, MA, October 31, 2005 - Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced today that N. Anthony Coles, M.D., has resigned his position with the Company General Business	View HTML Vertex Pharmaceuticals Announces Resignation of N. Anthony Coles, M.D., as Senior Vice President, Commercial Operations 7.6 KB
Toggle SummaryOct 26, 2005	Vertex Pharmaceuticals Reports Third Quarter 2005 Financial Results - VX-950 Phase Ib Combination Study Initiated -<BR> - Target Enrollment in VX-702 Phase II Rheumatoid Arthritis Study Achieved - General Business	View HTML Vertex Pharmaceuticals Reports Third Quarter 2005 Financial Results 303.4 KB
Toggle SummaryOct 4, 2005	Vertex Pharmaceuticals to Focus 2006 Clinical Development on Therapies for Hepatitis C Virus Infection, Inflammation and Cystic Fibrosis Vertex Pharmaceuticals to Focus 2006 Clinical Development on Therapies for Hepatitis C Virus Infection, Inflammation and Cystic Fibrosis Cambridge, MA, October 4, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it will concentrate its development investment in 2006 on HCV	View HTML Vertex Pharmaceuticals to Focus 2006 Clinical Development on Therapies for Hepatitis C Virus Infection, Inflammation and Cystic Fibrosis 15.8 KB
Toggle SummaryOct 3, 2005	New Data Suggest Vertex's Oral Hepatitis C Virus Protease Inhibitor VX-950 May Reduce Liver Injury; VX-950 Clinical Milestones on Track New Data Suggest Vertex's Oral Hepatitis C Virus Protease Inhibitor VX-950 May Reduce Liver Injury; VX-950 Clinical Milestones on Track Montreal, Canada, October 3, 2005 - New data show that patients with genotype 1 hepatitis C virus (HCV) infection treated with VX-950, an investigational oral HCV HCV	View HTML New Data Suggest Vertex's Oral Hepatitis C Virus Protease Inhibitor VX-950 May Reduce Liver Injury; VX-950 Clinical Milestones on Track 12.8 KB